{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:00:25Z","timestamp":1790085625193,"version":"4.0.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119876","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:29:39Z","timestamp":1788964179000},"page":"119876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["BET inhibitor apabetalone suppresses the fibrotic activation of cardiac fibroblasts associated with heart dysfunction"],"prefix":"10.1016","volume":"203","author":[{"given":"Sylwia","family":"Wasiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3194-0324","authenticated-orcid":false,"given":"Dean","family":"Gilham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Tsujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Carestia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-6323","authenticated-orcid":false,"given":"Christopher D.","family":"Sarsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqi","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine D.","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Fatehi","family":"Hassanabad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.M.","family":"Fedak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5428-3008","authenticated-orcid":false,"given":"Ewelina","family":"Kulikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119876_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.addr.2019.05.011","article-title":"Cardiac fibrosis - a short review of causes and therapeutic strategies","volume":"146","author":"Hinderer","year":"2019","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119876_bib2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jacbts.2019.02.006","article-title":"Fibroblasts in the Infarcted, Remodeling, and Failing Heart","volume":"4","author":"Humeres","year":"2019","journal-title":"JACC Basic. Transl. Sci."},{"key":"10.1016\/j.biopha.2026.119876_bib3","article-title":"Cardiac fibroblasts in myocardial injury and heart failure","author":"Van Linthout","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2026.119876_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ph17030267","article-title":"Hitting the target! Challenges and opportunities for TGF-beta inhibition for the treatment of cardiac fibrosis","volume":"17","author":"Vistnes","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.biopha.2026.119876_bib5","doi-asserted-by":"crossref","first-page":"C1893","DOI":"10.1152\/ajpcell.01043.2024","article-title":"The theatrics of collagens in the myocardium: the supreme architect of the fibrotic heart","volume":"328","author":"Chakraborty","year":"2025","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"10.1016\/j.biopha.2026.119876_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212262","article-title":"Cytokine-mediated alterations of human cardiac fibroblast's secretome","volume":"22","author":"Brauninger","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119876_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.017025","article-title":"Defining the cardiac fibroblast secretome in a fibrotic microenvironment","volume":"9","author":"Ceccato","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2026.119876_bib8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF02147594","article-title":"Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction","volume":"27","author":"Gabbiani","year":"1971","journal-title":"Experientia"},{"key":"10.1016\/j.biopha.2026.119876_bib9","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1091\/mbc.12.9.2730","article-title":"Alpha-smooth muscle actin expression upregulates fibroblast contractile activity","volume":"12","author":"Hinz","year":"2001","journal-title":"Mol. Biol. Cell."},{"key":"10.1016\/j.biopha.2026.119876_bib10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bph.15450","article-title":"Preclinical rodent models of cardiac fibrosis","volume":"179","author":"Wang","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119876_bib11","article-title":"The pivotal role of TGF-beta\/Smad pathway in fibrosis pathogenesis and treatment","volume":"15","author":"Chen","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119876_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109826","article-title":"The role of Smad signaling cascades in cardiac fibrosis","volume":"77","author":"Hanna","year":"2021","journal-title":"Cell. Signal."},{"key":"10.1016\/j.biopha.2026.119876_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241390","article-title":"Maintaining resting cardiac fibroblasts in vitro by disrupting mechanotransduction","volume":"15","author":"Gilles","year":"2020","journal-title":"PloS. One"},{"key":"10.1016\/j.biopha.2026.119876_bib14","article-title":"Transcriptional regulation of cardiac fibroblast phenotypic plasticity","volume":"28","author":"Burgos Villar","year":"2022","journal-title":"Curr. Opin. Physiol."},{"key":"10.1016\/j.biopha.2026.119876_bib15","article-title":"Chromatin remodeling drives immune-fibroblast crosstalk in heart failure pathogenesis","author":"Alexanian","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2026.119876_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41586-024-08008-5","article-title":"Targeting immune-fibroblast cell communication in heart failure","volume":"635","author":"Amrute","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119876_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40364-024-00641-6","article-title":"BRD4: an effective target for organ fibrosis","volume":"12","author":"Wei","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.biopha.2026.119876_bib18","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1161\/CIRCRESAHA.119.315125","article-title":"Dynamic chromatin targeting of BRD4 stimulates cardiac fibroblast activation","volume":"125","author":"Stratton","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.biopha.2026.119876_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202100180","article-title":"BRD4 in physiology and pathology: ''BET'' on its partners","volume":"43","author":"Liang","year":"2021","journal-title":"Bioessays"},{"key":"10.1016\/j.biopha.2026.119876_bib20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03674-1","article-title":"A transcriptional switch governs fibroblast activation in heart disease","volume":"595","author":"Alexanian","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119876_bib21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119876_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","article-title":"BET bromodomains mediate transcriptional pause release in heart failure","volume":"154","author":"Anand","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119876_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah5084","article-title":"BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure","volume":"9","author":"Duan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119876_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.148798","article-title":"Advances in BRD proteins in cardiovascular pathophysiology and therapy: a review","volume":"333","author":"Jiang","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2026.119876_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083190","article-title":"RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist","volume":"8","author":"McLure","year":"2013","journal-title":"PloS. One"},{"key":"10.1016\/j.biopha.2026.119876_bib26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/acsptsci.3c00219","article-title":"Apabetalone (RVX-208): a potential epigenetic therapy for the treatment of cardiovascular, renal, neurological, viral, and cancer disorders","volume":"7","author":"Dhulkifle","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.biopha.2026.119876_bib27","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.3308","article-title":"Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes: a randomized clinical trial","author":"Ray","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2026.119876_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12933-020-01199-x","article-title":"Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study","volume":"20","author":"Nicholls","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.biopha.2026.119876_bib29","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13148-020-00943-0","article-title":"BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes","volume":"12","author":"Wasiak","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.biopha.2026.119876_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13148-019-0696-z","article-title":"Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism","volume":"11","author":"Tsujikawa","year":"2019","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.biopha.2026.119876_bib31","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ekir.2017.12.001","article-title":"Benefit of apabetalone on plasma proteins in renal disease","volume":"3","author":"Wasiak","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.biopha.2026.119876_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11061663","article-title":"Apabetalone downregulates fibrotic, inflammatory and calcific processes in renal mesangial cells and patients with renal impairment","volume":"11","author":"Gilham","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119876_bib33","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1164\/rccm.201812-2275OC","article-title":"Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension","volume":"200","author":"Van der Feen","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2026.119876_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040437","article-title":"Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-Cov-2 infection in vitro","volume":"9","author":"Gilham","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119876_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16158-7","article-title":"A strategy to quantify myofibroblast activation on a continuous spectrum","volume":"12","author":"Hillsley","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119876_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.carpath.2014.06.003","article-title":"Human cardiac fibroblast extracellular matrix remodeling: dual effects of tissue inhibitor of metalloproteinase-2","volume":"23","author":"Ngu","year":"2014","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.biopha.2026.119876_bib37","first-page":"543","article-title":"Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.biopha.2026.119876_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1228232","article-title":"Endotrophin, a fibroblast matrikine, may be a driver of fibroblast activation in fibro-inflammatory diseases","volume":"10","author":"Reese-Petersen","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biopha.2026.119876_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113230","article-title":"Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators","volume":"152","author":"Tsujikawa","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119876_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10741-023-10361-y","article-title":"The role of periostin in cardiac fibrosis","volume":"29","author":"Qiao","year":"2024","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.biopha.2026.119876_bib41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.yjmcc.2015.11.014","article-title":"The role of secreted protein acidic and rich in cysteine (SPARC) in cardiac repair and fibrosis: does expression of SPARC by macrophages influence outcomes?","volume":"93","author":"Bradshaw","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.biopha.2026.119876_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115914","article-title":"Fibroblast activation protein: pivoting cancer\/chemotherapeutic insight towards heart failure","volume":"219","author":"Gehris","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119876_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdev.2025.204023","article-title":"Extracellular matrix in cardiac morphogenesis, fibrosis, and regeneration","volume":"182","author":"Punde","year":"2025","journal-title":"Cells Dev."},{"key":"10.1016\/j.biopha.2026.119876_bib44","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1083\/jcb.142.3.873","article-title":"The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1","volume":"142","author":"Serini","year":"1998","journal-title":"J. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119876_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2022.151253","article-title":"Collagen gel contraction assays: From modelling wound healing to quantifying cellular interactions with three-dimensional extracellular matrices","volume":"101","author":"Zhang","year":"2022","journal-title":"Eur. J. Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119876_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/wound.2011.0311","article-title":"Collagen organization critical role in wound contraction","volume":"1","author":"Ehrlich","year":"2012","journal-title":"Adv. Wound Care (New Rochelle)"},{"key":"10.1016\/j.biopha.2026.119876_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk8501","article-title":"Integration mapping of cardiac fibroblast single-cell transcriptomes elucidates cellular principles of fibrosis in diverse pathologies","volume":"10","author":"Patrick","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2026.119876_bib48","doi-asserted-by":"crossref","first-page":"410","DOI":"10.7150\/ijbs.113825","article-title":"Meox1 promotes cardiac fibrosis and pathological remodeling following myocardial infarction through Cthrc1\/p-Smad2\/3 signaling","volume":"22","author":"Zhang","year":"2026","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2026.119876_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41427-020-0226-7","article-title":"Control of fibroblast shape in sequentially formed 3D hybrid hydrogels regulates cellular responses to microenvironmental cues","volume":"12","author":"Liu","year":"2020","journal-title":"NPG Asia Mater."},{"key":"10.1016\/j.biopha.2026.119876_bib50","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.celrep.2014.08.025","article-title":"Inducible in vivo silencing of Brd4 identifies potential toxicities of sustained BET protein inhibition","volume":"8","author":"Bolden","year":"2014","journal-title":"Cell. Rep."},{"key":"10.1016\/j.biopha.2026.119876_bib51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2014.06.008","article-title":"A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice","volume":"236","author":"Jahagirdar","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2026.119876_bib52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2022.11.015","article-title":"Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells","volume":"364","author":"Wasiak","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2026.119876_bib53","article-title":"Design and evaluation of a polypeptide that mimics the integrin binding site for EDA fibronectin to block profibrotic cell activity","volume":"22","author":"Zhang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119876_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-04990-6","article-title":"Single-cell RNA sequencing reveals the potential role of Postn(+) fibroblasts in promoting the progression of myocardial fibrosis after myocardial infarction","volume":"15","author":"Nie","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119876_bib55","first-page":"1820","article-title":"Role of the lysyl oxidase enzyme family in cardiac function and disease","volume":"115","author":"Al-U'datt","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.biopha.2026.119876_bib56","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","article-title":"Targeting cardiac fibrosis with engineered T cells","volume":"573","author":"Aghajanian","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119876_bib57","article-title":"Cold and hot fibrosis define clinically distinct cardiac pathologies","volume":"16","author":"Miyara","year":"2025","journal-title":"Cell. Syst."},{"key":"10.1016\/j.biopha.2026.119876_bib58","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.cell.2021.03.026","article-title":"BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection","volume":"184","author":"Mills","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119876_bib59","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/03936155251335975","article-title":"Identification of MEOX1 as a potential target in metabolic dysfunction-associated steatohepatitis-related liver fibrosis","volume":"40","author":"Jiao","year":"2025","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.biopha.2026.119876_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.178043","article-title":"Transcription factor MEOX1 accelerates pulmonary fibrosis by regulating mitophagy and senescence","volume":"1005","author":"Fang","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119876_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/ejhf\/xuag034.023","article-title":"F. The BET protein inhibitor apabetalone rescues cardiometabolic heart failure with preserved ejection fraction by suppressing myocardial and systemic inflammation: a study in mice and humans","volume":"28","author":"Di Venanzio","year":"2026","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2026.119876_bib62","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4142848","article-title":"F. Abstract 4142848: Apabetalone protects against heart failure with preserved ejection fraction by suppressing myocardial inflammation","volume":"150","author":"Costantino","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2026.119876_bib63","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2019.02.049","article-title":"Myofibroblast phenotype and reversibility of fibrosis in patients with end-stage heart failure","volume":"73","author":"Nagaraju","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2026.119876_bib64","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jacc.2024.10.103","article-title":"Myocardial fibroblast activation after acute myocardial infarction: a positron emission tomography and magnetic resonance study","volume":"85","author":"Barton","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2026.119876_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocmr.2024.101064","article-title":"Remote myocardial fibrosis predicts adverse outcome in patients with myocardial infarction on clinical cardiovascular magnetic resonance imaging","volume":"26","author":"Black","year":"2024","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"10.1016\/j.biopha.2026.119876_bib66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2018.11.002","article-title":"Apabetalone downregulates factors and pathways associated with vascular calcification","volume":"280","author":"Gilham","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2026.119876_bib67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2016.01.036","article-title":"RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I\/HDL and represses pathways that contribute to cardiovascular disease","volume":"247","author":"Gilham","year":"2016","journal-title":"Atherosclerosis"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:07:47Z","timestamp":1790082467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":67,"alternative-id":["S0753332226009121"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119876","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BET inhibitor apabetalone suppresses the fibrotic activation of cardiac fibroblasts associated with heart dysfunction","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Resverlogix Corp. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119876"}}